Sparrow Pharmaceuticals Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Mezzanine

  • Latest Deal Amount
  • $10M

  • Investors
  • 9

Sparrow Pharmaceuticals General Information

Description

Operator of a pharmaceutical company intended to develop treatments for disorders of corticosteroid excess. The company offers targeted therapies for conditions of corticosteroid excess associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone, enabling clients to provide improved treatment options for serious disorders of hypercortisolism and revolutionize the treatment of autoimmune and inflammatory conditions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 1050 South West 6th Avenue
  • Suite 1100
  • Portland, OR 97204
  • United States
+1 (617) 000-0000

Sparrow Pharmaceuticals Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sparrow Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Mezzanine 12-Apr-2024 $10M 000.00 Completed Generating Revenue
5. Later Stage VC (Series A) 01-Jun-2021 000.00 000.00 0000 Completed Clinical Trials - General
4. Grant 15-Apr-2019 00000 Completed Clinical Trials - General
3. Accelerator/Incubator 01-Jan-2019 Completed Clinical Trials - General
2. Accelerator/Incubator 28-Oct-2014 Completed Startup
1. Merger/Acquisition Completed Startup
To view Sparrow Pharmaceuticals’s complete valuation and funding history, request access »

Sparrow Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Sparrow Pharmaceuticals’s complete cap table history, request access »

Sparrow Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a pharmaceutical company intended to develop treatments for disorders of corticosteroid excess. The company
Drug Discovery
Portland, OR
10 As of 2023
000.00
000000000000 000.00

000000

ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercit
0000 000000000
Palo Alto, CA
00 As of 0000
00000
000000 - 000 00000

000 00

iqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut
0000 000000000
Belfast, United Kingdom
00 As of 0000
00.000
0000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sparrow Pharmaceuticals Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Evommune Venture Capital-Backed Palo Alto, CA 00 00000 000000 - 000 00000
CV6 Therapeutics Venture Capital-Backed Belfast, United Kingdom 00 00.000 0000000000 00.000
SFA Therapeutics Venture Capital-Backed Jenkintown, PA 00 000.00 0000000000 0 000.00
You’re viewing 3 of 3 competitors. Get the full list »

Sparrow Pharmaceuticals Patents

Sparrow Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230364060-A1 Methods and compositions for treating glucocorticoid excess Pending 16-May-2022 00000000000 0
AU-2019384074-A1 Methods for administering corticosteroids Pending 20-Nov-2018 0000000000
CA-3120339-A1 Methods for administering corticosteroids Pending 20-Nov-2018 0000000000
EP-3883578-A4 Methods for administering corticosteroids Pending 20-Nov-2018 0000000000 0
EP-3883578-A1 Methods for administering corticosteroids Pending 20-Nov-2018 A61K31/496
To view Sparrow Pharmaceuticals’s complete patent history, request access »

Sparrow Pharmaceuticals Executive Team (5)

Name Title Board Seat Contact Info
Robert Jacks Chief Executive Officer, President & Board Member
David Katz Ph.D Founder & Chief Scientific Officer
Jeffrey Drajesk Vice President of Program Management
Frank Czerwiec Ph.D Chief Medical Officer
Klaus Veitinger Ph.D Chairman
To view Sparrow Pharmaceuticals’s complete executive team members history, request access »

Sparrow Pharmaceuticals Board Members (7)

Name Representing Role Since
Jon Root Self Board Member 000 0000
Klaus Veitinger Ph.D Self Chairman 000 0000
Niall O'Donnell Ph.D RiverVest Venture Partners Board Member 000 0000
Peter Thompson MD OrbiMed Board Member 000 0000
Robert Jacks Sparrow Pharmaceuticals Chief Executive Officer, President & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Sparrow Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sparrow Pharmaceuticals Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Keiretsu Forum Angel Group Minority 000 0000 000000 0
OrbiMed Growth/Expansion Minority 000 0000 000000 0
U.S. Venture Partners Venture Capital Minority 000 0000 000000 0
Business Oregon Government 000 0000 000000 0
OTRADI Bioscience Incubator Accelerator/Incubator 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Sparrow Pharmaceuticals FAQs

  • When was Sparrow Pharmaceuticals founded?

    Sparrow Pharmaceuticals was founded in 2013.

  • Who is the founder of Sparrow Pharmaceuticals?

    David Katz Ph.D is the founder of Sparrow Pharmaceuticals.

  • Who is the CEO of Sparrow Pharmaceuticals?

    Robert Jacks is the CEO of Sparrow Pharmaceuticals.

  • Where is Sparrow Pharmaceuticals headquartered?

    Sparrow Pharmaceuticals is headquartered in Portland, OR.

  • What is the size of Sparrow Pharmaceuticals?

    Sparrow Pharmaceuticals has 10 total employees.

  • What industry is Sparrow Pharmaceuticals in?

    Sparrow Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Sparrow Pharmaceuticals a private or public company?

    Sparrow Pharmaceuticals is a Private company.

  • What is Sparrow Pharmaceuticals’s current revenue?

    The current revenue for Sparrow Pharmaceuticals is 000000.

  • How much funding has Sparrow Pharmaceuticals raised over time?

    Sparrow Pharmaceuticals has raised $60.8M.

  • Who are Sparrow Pharmaceuticals’s investors?

    Keiretsu Forum, OrbiMed, U.S. Venture Partners, Business Oregon, and OTRADI Bioscience Incubator are 5 of 9 investors who have invested in Sparrow Pharmaceuticals.

  • Who are Sparrow Pharmaceuticals’s competitors?

    Evommune, CV6 Therapeutics, and SFA Therapeutics are competitors of Sparrow Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »